Achelios Therapeutics to present results of Phase 1b-2a TOPOFEN™ migraine study at American Academy of Neurology Session on Emerging Science on April 22. TOPOFEN™, a new topical medication for the treatment of acute migraine. Achelios Therapeutics (privately held, Chapel Hill, NC) today announced results from a Phase IIa placebo-controlled clinical trial in moderate and severe migraine sufferers treated with TOPOFEN™ (ELS-M11), the company’s proprietary topical anti-migraine therapy. The data presented demonstrate that the simple application of a well-known non-steroidal anti-inflammatory drug (NSAID), using the company’s proprietary formulation, on the skin, over the trigeminal nerve branches, can be a safe and effective alternative treatment for patients suffering from acute migraine. William R. Bauer M.D., Ph.D., FAAN, a neurologist and migraine headache specialist and advisor to Achelios, says, “Migraine remains a significant global cause of disability and disruption of activities of daily living. TOPOFEN™ results show promise to provide a sa
Main Neurophysiological Tools?
Neurophysiological tools used in migraine research are noninvasive, and most of them are portable devices that are accessible at a relatively low cost. The main techniques are electroencephalography (EEG and more recently magneto-EEG or MEG, a recording of spontaneous cerebral activity), evoked potentials (EPs, i.e., cerebral activity recorded in response to a visual, auditory, or painful stimulus), and the nociception-specific blink reflex (nsBR, an evaluation of trigeminal nociception). Another important tool is transcranial magnetic stimulation (TMS), which can modify brain excitability.
What Symptoms Occur During a Migraine Attack?
Migraineurs have recurrent, severe, and disabling attacks of headache, often unilateral and pulsating, along with symptoms of sensory disturbance, such as light, sound, and odor sensitivity. Nausea and neck stiffness are other common symptoms, and symptoms can be aggravated by movement.